Traduction de «oral contraceptive use in women » (Néerlandais → Français) :

compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ
drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States

Use of combined oral contraceptives among women with migraine and
Use of combined oral contraceptives among women with

Naar D.M. Grabrick et al.: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer.
D’après D.M. Grabrick et al.: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer.

Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone
Risk of non-fatal venous thromboembolism in women using oral contraceptives containing

(Chan 2004) Chan WS, Ray J, Wai EK et al. Risk of stroke in women exposed to low-dose oral contraceptives.
(CGESOC 2008) Collaborative Group on Epidemiological Studies of Ovarian Cancer.

European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation.
from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation.

Is there an association between the use of oral contraception and depressive symptoms in young
Is there an association between the use of oral contraception and depressive

(Jernström 2005) Jernström H, Loman N, Johansson OT et al. Impact of teenage oral contraceptive use in a population-based series of earlyonset breast cancer cases who have undergone BRCA mutation testing. Eur J Cancer 2005; 41:2312-20.
(Jernström 2005) Jernström H, Loman N, Johansson OT et al. Impact of teenage oral contraceptive use in a population-based

The use of Femara, an oral therapy for postmenopausal women with hormone sensitive breast cancer, has driven approximately 70% of overall aromatase inhibitor market segment growth around the world, particularly in the initial adjuvant (post-surgery) setting (Source: IMS Health Q4 2009).
L’utilisation de Femara, traitement par voie orale pour les femmes postménopausées atteintes d’un cancer du sein hormonodépendant, a représenté quelque 70% de la croissance mondiale du segment de marché de l’inhibiteur de l’aromatase, notamment en tant que traitement adjuvant (post-chirurgical) de première intention.